| |MAY 20268TOP STORIESCOHANCE LIFESCIENCES NAMES UMANG VOHRA AS CEO & CHAIRMANZYDUS GETS NOD FOR PHASE III CLINICAL TRIALS OF ZINTRODIAZINE IN INDIAINDIAN IMMUNOLOGICALS ACHIEVES RECORD REVENUE OF RS1,586 CRORE IN FY26CENTRE CONFIRMS NO CHANGE IN TB TREATMENT REGIMEN ACROSS INDIACohance Lifesciences has appointed Umang Vohra as its new Executive Chairman and Group CEO, marking a major leadership shift aimed at driving growth.The company said Umang Vohra will take charge as Executive Chairman from May 1, 2026, and step in as Group CEO from May 20, 2026. This move places Cohance Lifesciences at a critical turning point as it looks to strengthen its global position.Vohra succeeds Vivek Sharma, who has stepped down from his role for personal reasons. However, Sharma will continue to support the company as an advisor for the next nine months to ensure a smooth transition. The leadership change comes at a time when the company is looking to sharpen execution and accelerate expansion. POZydus Lifesciences Limited has received approval to begin Phase III clinical trials of Zintrodiazine for treating malaria in India, marking a key step in its push to develop new therapies against the disease.The company said the Zintrodiazine trials will focus on patients with uncomplicated infections caused by Plasmodium falciparum and Plasmodium vivax.Indian Immunologicals Limited has reported its highest-ever annual revenue of 1,586 crore for the financial year 2025­26, marking a major milestone in the company's growth. The strong performance reflects increasing demand for vaccine manufacturing, animal healthcare, and human healthcare products across India.Based in India, the company has steadily expanded its presence in the Indian vaccine market through continuous investment in research and development, manufacturing, and product innovation. The latest revenue figures highlight the company's growing influence in the healthcare industry and its ability to meet rising demand. POThe Union Health Ministry has clarified that there has been no change in the treatment plan for Tuberculosis treatment in India, countering misleading claims circulating on social media. Recent online posts suggested that the country had adopted a new TB treatment regimen, creating confusion among patients and healthcare providers.Health officials stated that the existing six-month TB treatment protocol under the National TB Elimination Programme continues to remain in place. The Centre emphasized that no official decision has been made to replace the current system, which is followed in hospitals and healthcare centres across India.The confusion mainly stemmed from claims about a shorter treatment method known as the HPMZ regimen. This therapy combines four medicines and has been discussed in global research studies. However, authorities clarified that the regimen has not been approved for nationwide use and remains under evaluation by health experts. POBoth studies will be multi-center, randomized, assessor-blind, and use active comparators to evaluate the drug's efficacy, safety, and tolerability when taken orally.The first Phase III trial will enroll 651 patients with P. falciparum malaria. The second will include 390 patients with P. vivax mono-infection. In both trials, the primary goal is to measure effectiveness using PCR-adjusted adequate clinical and parasitological response (ACPR). Researchers will also track secondary outcomes such as recrudescence, new infections, parasite clearance time, and fever resolution. PO
< Page 7 | Page 9 >